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RESEARCH
LC–MS/MS-based in vitro and in vivo 
investigation of blood–brain barrier integrity 
by simultaneous quantitation of mannitol 
and sucrose
Behnam Noorani1,4, Ekram Ahmed Chowdhury1,4, Faleh Alqahtani2, Yeseul Ahn1,4, Dhavalkumar Patel1, 
Abraham Al‑Ahmad1,4, Reza Mehvar3 and Ulrich Bickel1,4* 
Abstract 
Background: Understanding the pathophysiology of the blood brain–barrier (BBB) plays a critical role in diagnosis 
and treatment of disease conditions. Applying a sensitive and specific LC–MS/MS technique for the measurement of 
BBB integrity with high precision, we have recently introduced non‑radioactive  [13C12]sucrose as a superior marker 
substance. Comparison of permeability markers with different molecular weight, but otherwise similar physicochemi‑
cal properties, can provide insights into the uptake mechanism at the BBB. Mannitol is a small hydrophilic, uncharged 
molecule that is half the size of sucrose. Previously only radioactive  [3H]mannitol or  [14C]mannitol has been used to 
measure BBB integrity.
Methods: We developed a UPLC–MS/MS method for simultaneous analysis of stable isotope‑labeled sucrose and 
mannitol. The in vivo BBB permeability of  [13C6]mannitol and  [
13C12]sucrose was measured in mice, using  [
13C6]sucrose 
as a vascular marker to correct for brain intravascular content. Moreover, a Transwell model with induced pluripotent 
stem cell‑derived brain endothelial cells was used to measure the permeability coefficient of sucrose and mannitol 
in vitro both under control and compromised (in the presence of IL‑1β) conditions.
Results: We found low permeability values for both mannitol and sucrose in vitro (permeability coefficients of 
4.99 ± 0.152 × 10−7 and 3.12 ± 0.176 × 10−7 cm/s, respectively) and in vivo (PS products of 0.267 ± 0.021 and 
0.126 ± 0.025 µl  g−1  min−1, respectively). Further, the in vitro permeability of both markers substantially increased in 
the presence of IL‑1β. Corrected brain concentrations  (Cbr), obtained by washout vs. vascular marker correction, were 
not significantly different for either mannitol (0.071 ± 0.007 and 0.065 ± 0.009 percent injected dose per g) or sucrose 
(0.035 ± 0.003 and 0.037 ± 0.005 percent injected dose per g). These data also indicate that  Cbr and PS product values 
of mannitol were about twice the corresponding values of sucrose.
Conclusions: We established a highly sensitive, specific and reproducible approach to simultaneously measure the 
BBB permeability of two classical low molecular weight, hydrophilic markers in a stable isotope labeled format. This 
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zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Open Access
Fluids and Barriers of the CNS
*Correspondence:  Ulrich.Bickel@ttuhsc.edu
1 Department of Pharmaceutical Sciences, Jerry H. Hodge School 
of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 
79106, USA
Full list of author information is available at the end of the article
Page 2 of 15Noorani et al. Fluids Barriers CNS           (2020) 17:61 
Introduction
The blood–brain barrier (BBB) maintains the homeo-
static environment of the CNS by separating circulating 
blood from the central nervous system [1]. It encom-
passes specialized endothelial cells with a basal lamina 
that supports the abluminal surface of the endothelium 
along with other supporting cells, such as pericytes, 
astrocytes, and neurons [1]. The brain microvascular 
endothelial cells with tight junctions and transporter 
proteins are the primary and main gatekeepers for the 
transportation of nutrients and metabolites, and for the 
efflux of neurotoxins [2, 3]. The BBB dysfunction and 
breakdown contribute to neurological disorders due 
to the transfer of harmful blood components into the 
brain, irregular transport, and dysregulated clearance of 
metabolites associated with reduced cerebral blood flow 
[4]. Therefore, measuring the functional integrity of BBB 
by various methods such as paracellular markers is fre-
quently performed in in vitro and in vivo studies.
There are many technical and conceptual pitfalls asso-
ciated with the experimental application of supposedly 
paracellular markers and the subsequent interpretation 
of data. One important aspect, which deserves mention-
ing, is the fact that these markers can serve two distinct 
purposes. The first purpose is that, due to their charac-
teristically low BBB permeability, these substances are 
often used as so-called vascular markers. This is com-
monly the case when other, more permeable agents are 
measured in the same study. When used as a vascular 
marker, it is assumed that neglecting the extent of brain 
uptake of the substance during a short experimental time 
period (1 minute or less) does not significantly compro-
mise the study. Therefore, any concentration measured 
in whole brain tissue presumably represents brain intra-
vascular space (with reference to concentration in whole 
blood), or brain plasma volume (with reference to plasma 
concentration). Such intravascular space values can then 
be used to correct brain concentrations of other sub-
stances, before calculating their BBB permeability. The 
second purpose is to determine the genuine permeability 
values of the BBB markers themselves, which is not zero. 
The latter measurement, of course, also requires proper 
correction for intravascular volume. Major damage to the 
BBB, caused by severe disease processes, such as stroke 
or a relapse phase of multiple sclerosis, may be readily 
detected using various imaging techniques and a range 
of markers. However, for the quantification of subtle 
BBB impairment, markers with naturally low permeabil-
ity, such as sucrose or mannitol, are used, because even 
a minor degree of barrier damage is expected to have a 
noticeable effect on their permeability. Such damage has 
been observed in acute situations, for instance caused by 
peripheral inflammatory pain [5, 6], and after major sur-
gery, where it has been connected to the occurrence of 
postoperative cognitive dysfunction in animal studies [7] 
and in patients [8]. Subtle BBB damage has also been pos-
tulated to play a role in the pathophysiology of chronic 
diseases like Alzheimer’s dementia [9] or small vessel dis-
ease [10]. However, there is still uncertainty, as functional 
BBB changes related to drug transport could not be con-
firmed in animal models of Alzheimer’s disease [11, 12].
Radiolabeled versions of sucrose, in particular  [14C]
sucrose, have long been used as low molecular weight, 
hydrophilic markers. We have recently introduced  [13C12]
sucrose as a superior marker substance, which is non-
radioactive and can be quantified by a sensitive and 
highly specific LC–MS/MS technique [13, 14]. The disac-
charide sucrose may be considered as the most widely 
accepted standard for the precise measurement of para-
cellular BBB permeability due to its properties, such as 
being uncharged, absence of protein binding, and meta-
bolic stability in the circulation [15]. Our lab has focused 
on understanding the uptake mechanism at the BBB of 
different molecular weight markers, which have similar 
physicochemical properties. Mannitol is a small molecule 
that is about half the size of sucrose and has otherwise 
similar characteristics as sucrose as a marker for the BBB. 
It also has a molecular weight (182  Da) in the range of 
many small-molecule drugs.
Furthermore, mannitol has been widely used over 
the last 30 years in the lactulose/mannitol (L/M) test as 
a common dual-sugar test to assess the intestinal bar-
rier function [16]. The radiotracer version of mannitol 
has been used for measurement of BBB integrity, but it 
requires a radioactive license and special handling skills 
[17–22]. We have also shown that using the radiolabeled 
versions of a marker, in particular  [14C]sucrose, might 
result in a substantial overestimation of the true BBB per-
meability due to the presence of low level lipid-soluble 
impurities in the radiolabeled versions of the marker.
The first objective of the present study was to develop 
a UPLC–MS/MS method, which allows simultaneous 
method is now available as a tool to quantify BBB permeability in vitro and in vivo in different disease models, as well 
as for monitoring treatment outcomes.
Keywords: Blood–brain barrier, Mannitol, Sucrose, Vascular space correction, Permeability coefficient, Brain uptake 
clearance, In vitro and in vivo correlation
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analysis of stable isotope-labeled sucrose and mannitol. 
The second objective was to show the application of these 
markers in BBB in an vitro and in vivo model. The appli-
cation of a stable isotope-labeled version of mannitol as 
a marker for BBB has not been reported yet. Different 
stable isotope-labeled versions of mannitol and sucrose, 
respectively, are commercially available. The variants of 
each marker coelute from a BEH-amide UPLC column, 
but are separate from each other. This allowed the simul-
taneous use of both markers for BBB permeability analy-
sis. Furthermore, for the first time, one variant of  [13C]
sucrose was used to correct vascular space for mannitol 
and sucrose simultaneously. Thus, we selected a suit-
able combination of mass transitions and settings of the 
mass detector to detect and quantify  [13C6]mannitol and 
 [13C12]sucrose as permeability markers,  [2H8]mannitol 
and  [2H2]sucrose as internal standards, and  [13C6]sucrose 
as a vascular marker. Our method offers novel accurate 
biomarkers of different sizes for permeability measure-
ments of the BBB in the preclinical phase.
Methods
Chemicals and reagents
[13C6]mannitol,  [2H8]mannitol,  [13C12]sucrose,  [13C6]
sucrose, and  [2H2]sucrose were obtained from Omicron 
Biochemicals (South Hill Street, South Bend, IN, USA). 
LC–MS grade water was purchased under the brand 
name J.T. Baker from Avantor Performance Materials, 
Inc. (Center Valley, PA). LC–MS/MS grade acetonitrile, 
water, and analytical grade ammonium hydroxide were 
purchased from Fisher Scientific (Fair Lawn, NJ, USA). 
For anesthesia, isoflurane was purchased from Lloyd 
Laboratories (Shenandoah, IA, USA). Heparin solution 
was purchased from APP Pharmaceuticals (Schaumburg, 
IL, USA). All other chemicals were analytical grade and 
obtained from commercial sources.
Mass spectrometric and chromatographic conditions
Analytes were detected using an AB SCIEX  QTRAP® 
5500 triple quadrupole mass spectrometer (MS) attached 
to a Nexera UPLC system (Shimadzu Corporation). The 
UPLC system contained an autosampler (Sil-30AC), 
pumps (LC-30AD), a controller (CBM-20A), a degasser 
(DGA-20A5), and a column oven (CTO-30A). Analyst 
software was used for data acquisition and quantification. 
Chromatographic separation was performed using an 
Acquity B.E.H. amide (2.1 mm × 50 mm, 1.7 μm; Waters, 
Milford, MA, USA), attached to an inline filter with a 
pore size of 0.2 μm as a pre-column. The isocratic elution 
was acetonitrile: water: ammonium hydroxide (73:27:0.1, 
v/v), at a flow rate of 0.2 mL/min. The column tempera-
ture was maintained at 45  °C, and the autosampler was 
at 4 °C. The total run time was 6 min. However, MS data 
were collected from 1 to 4.5 min only, and the valve was 
diverted to waste before and after that time. Electrospray 
ionization with multiple reactions monitoring system in 
negative mode was used for the ionization source. The 
mass spectrometer parameters for  [13C12]sucrose,  [13C6]
sucrose and  [2H2]sucrose were optimized in our previous 
study [13], however,  [13C6] and  [2H2]sucrose mass spec-
trometer parameters were changed due to presence of an 
interfering peak in the blank plasma and brain samples at 
the same retention time when combined with mannitol 
transitions. The mass spectrometer conditions for  [13C6] 
and  [2H8]mannitol were optimized to get optimum M−
H−1 signal by continuous infusion of 100 ng/ml manni-
tol solution with an infusion pump. The optimized mass 
spectrometer parameters were as follows: ion spray volt-
age, − 4500 V; collision gas, high; curtain gas, 30 psi; tem-
perature, 600 °C; ion source gas 1 (nebulizer gas), 55 psi; 
and ion source gas 2 (turbo gas), 55 psi.
For  [13C6] and  [2H8]mannitol, the m/z transitions 
187 → 92 and 189 → 73 were selected, respectively. Also, 
the transitions 353 → 92, 347 → 179 and 343 → 71 were 
used for  [13C12],  [13C6] and  [2H2]sucrose.
Standard curve preparation
Stock solutions of triple analytes  [13C6] mannitol,  [13C12], 
and  [13C6]sucrose were prepared in water at a concentra-
tion of 10  mg/mL. Plasma standard curves were made 
by adding blank mouse plasma to stock solutions to get 
plasma concentrations of 1–100 μg/mL. Then, each con-
centration was diluted 100-fold in water to obtain spe-
cific plasma calibration standards of 10–1000  ng/mL. 
For brain standard curve, blank brain tissue was homog-
enized in water (1:19), and triple analytes were spiked 
into the homogenized brain. Homogenate concentrations 
ranging from 5 to 400  ng/mL were prepared by serial 
dilution.
Sample preparation
For the deproteination process, all samples were diluted 
tenfold in acetonitrile: water (80:20) containing 20  ng/
mL of  [2H2]sucrose and  [2H8]mannitol. Then, precipi-
tated samples were vortexed and centrifuged at 20,000g 
for 10 min. The supernatant was transferred into autosa-
mpler inserts, and a sample volume of 5 μL was injected 
into the UPLC column.
Method validation
Selectivity
Blank matrix samples from mice containing no analyte 
were run to obtain the selectivity of the method. Also, to 
ensure that there is no interference between analyte tran-
sitions, neat samples of single analytes without matrix 
were run.
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Accuracy and precision
Inter and intra-day runs were performed to determine 
the accuracy and precision of the method. The quality 
control samples (low, medium, and high concentra-
tions) were evaluated against calibration curves. The 
accuracy was calculated as a percentage of measured 
concentration over nominal concentration. Precision 
was calculated as a percentage of relative standard 
deviations (RSD). The acceptable inter and intra-run 
limits for the accuracy were set at 85–115% for the 
middle and high concentrations and 80–120% for the 
low concentration. The standard precision values were 
15% (medium and high concentrations) or 20% (low 
concentration).
Linearity
The linearity of calibration curves was evaluated by the 
coefficient of determination  (r2) of the linear regres-
sion analysis of the concentration–response data using 
a weight of 1/x, where x is the concentration. Weight-
ing by 1/x is superior to analysis with equal weights, on 
the strength of higher accuracy and less variability at low 
concentrations.
Recovery
The recovery of triple analytes was calculated in diluted 
plasma and homogenized brain. We expected similar 
recovery of the sucrose analytes as mentioned in the 
results described previously [13, 14] since all of the ana-
lytes are stable labeled isotopes of the same chemical 
entity. Three concentrations representing low, medium, 
and high were selected from the calibration curve. In 
case of plasma matrix, 10, 100, and 1000  ng/mL were 
used, and 5, 50, and 400  ng/mL were selected for the 
brain homogenate. Five replicate samples were prepared 
in each of the respective matrices, as well as samples with 
equivalent concentrations in water as reference. The sam-
ples and references were subjected to the sample prepa-
ration method described above, and the peak areas of 
analytes were determined. Recovery was calculated as 
the percent of the ratio of peak areas Sample/Reference, 
where sample refers to the matrix and reference to water 
(neat sample), respectively.
Freeze–thaw stability
The freeze–thaw stability was performed by subjecting 
two neat concentrations of analytes (50 and 500 ng/mL) 
to three freeze/thaw cycles (n = 3). Prepared samples 
were stored at − 80 °C and thawed at room temperature 
for 1 h, in order to replicate the experimental conditions. 
The concentration of the analytes in the neat samples was 
compared to the standard curve.
Long‑term stability
Long term storage stability of different isotope of sucrose 
was checked in our previous study [13]. In this section, 
long term stability of  [13C6]mannitol was evaluated for 
the diluted plasma samples and brain homogenate at 
− 80  °C. Quality control samples at low, medium and 
high concentrations of analyte in the brain and plasma 
(n = 3) were stored at − 80  °C for 2 months. The stored 
samples were then compared against standards in order 
to assess stability.
In vivo application of the method
Two groups of anesthetized C57BL/6J mice were used 
to perform the pharmacokinetic study. 8–10  weeks old 
female C57BL/6J mice with 23–27  g bodyweight were 
purchased from Jackson Laboratories (Bar Harbor, ME, 
USA). The experimental protocols were approved by 
the Institutional Animal Care and Use Committee at 
Texas Tech University Health Sciences Center and fol-
lowed current NIH guidelines. A silicone face mask was 
used to apply isoflurane (4% for induction, 1.5–2% v/v for 
maintenance) in 70% nitrous oxide/30% oxygen at a flow 
rate of 1 L/min. By skin incisions, the jugular veins were 
exposed bilaterally at the neck for IV injections and blood 
sampling, respectively.  [13C6]mannitol and  [13C12]sucrose 
(10  mg/kg) were co-injected as an IV bolus dose into 
the jugular vein. Then, at 1, 5, 10, 20, and 30  min after 
injection, blood samples (40 µL) were collected from 
the contralateral jugular vein. The samples were used to 
generate plasma concentration–time curves in each indi-
vidual animal. Two groups of animals were used to inves-
tigate the effect of  [13C6]sucrose application as vascular 
marker compared to transcardiac perfusion for vascular 
space correction (washout group). In the washout group 
(n = 6), the thorax was opened immediately after the last 
time point of sampling (30  min), and 20  mL phosphate 
buffered saline (pH 7.4) at room temperature, was used 
to perform the vascular perfusion via the left ventricle of 
the heart (flow rate of 2 mL/min) using a Harvard syringe 
pump. In order to facilitate the outflow of blood from the 
brain and to visually confirm the complete blood removal 
from the brain following perfusion, both jugular veins 
were cut open at the start of perfusion. In the second 
group of the animals (n = 6), a bolus dose of the vascular 
marker  [13C6]sucrose (10  mg/kg in saline) was injected 
intravenously 30  s before the last sampling time point. 
Afterwards, the animals were euthanized by decapita-
tion. Collected blood samples were centrifuged, and 
supernatant plasma was separated for further analysis. 
Meninges were removed from the collected brains, and 
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the forebrains were weighted without olfactory bulbs, 
cerebellum, or brain stem. Then, the brain and plasma 
samples homogenized and diluted respectively accord-
ing to the sample preparation steps described in UPLC-
MS/MS section and the homogenized brain and diluted 
plasma were stored at − 80 °C until measurement by the 
UPLC-MS/MS system.
The value of corrected brain concentration ( CAnalytebr−corr ) in 
the vascular marker group, which received  [13C6]sucrose, 
was determined as follows:
Here, Vd is the apparent volume of distribution of the 
BBB permeability marker,  [13C6]mannitol and  [13C12] 
sucrose, V0 is the apparent volume of distribution of the 
vascular marker,  [13C6] sucrose, and C
analyte
pl  is the termi-
nal (30  min) plasma concentration of  [13C6]mannitol or 
 [13C12]sucrose. Vd and V0 values were obtained using the 
following two equations.
where Canalytebr  is the total uncorrected brain concentra-
tion of  [13C6] mannitol or  [13C12]sucrose and 
Cvascular markerbr  is the total (uncorrected) brain concentra-
tions of  [13C6]sucrose, at the terminal sampling time 
(30 min), and Cvascular markerpl  is the terminal plasma con-
centration of the vascular marker at 30 min.
Brain tissue concentration values in the washout group, 
which had undergone buffer washout, were considered 
as corrected for intravascular content. Values for brain 
uptake clearance,  Kin, also known as the permeability-
surface area product, were calculated using the following 
equations based on either uncorrected ( Canalytebr  ) or cor-
rected ( Canalytebr−corr ) brain concentrations of mannitol and 
sucrose:
where AUC 0T denotes the area under the plasma concen-
tration–time curve from time point 0 to the terminal 
sampling time (30  min) for  [13C6]mannitol and  [13C12]
sucrose. AUC 0T was estimated via the linear-logarithmic 
trapezoidal method.
(1)CAnalytebr−corr =
(Vd − V0)× C
Analyte
pl
1− V0
(2)Vd = C
analyte
br /C
analyte
pl
(3)V0 = Cvascular markerbr /C
vascular marker
pl
(4)Kin = C
analyte
br /AUC
T
0
(5)Kin−corr = C
analyte
br−corr/AUC
T
0
For a comparison between in  vitro and in  vivo mod-
els, the  Kin values or permeability surface area products 
(PS) were converted to permeability coefficients, taking 
120 cm2/g of brain as the surface area of the BBB in vivo 
[23].
In vitro application of the method
iPSCs differentiation to BMECs
IMR90-c4 induced pluripotent stem cell line was used 
from the WiCell cell repository (WiCell, Madison, WI, 
USA). iPSCs were differentiated into brain microvascular 
endothelial cells (BMECs) following the established pro-
tocol [24, 25]. Undifferentiated stem cells were seeded on 
six well tissue culture treated plates coated with matrigel 
(C-Matrigel; Corning, Corning, MA, USA) in Essential 8 
medium (E8 Thermo Fisher, Waltham, MA, USA) con-
taining 10 μM Y-27632 (Tocris, Minneapolis, MN, USA) 
at a density of 100,000 cells/mL. Cells were maintained in 
E8 for 3 days prior to differentiation. Then, differentiation 
was initiated using unconditioned medium [UM: Dulbec-
co’s modified Eagle’s medium/F12 with 15  mM HEPES 
(Thermo Fisher, Waltham, MA, USA), 20% knockout 
serum replacement (Thermo Fisher, Waltham, MA, 
USA), 1% non-essential amino acids (Thermo Fisher, 
Waltham, MA, USA), 0.5% Glutamax (Thermo Fisher, 
Waltham, MA, USA) and 0.1  mM β-mercaptoethanol 
(Sigma-Aldrich, St. Louis, MO, USA)] and maintained 
for 6  days. After 6  days, cells were incubated for two 
days with EC++ media [human serum-free endothe-
lial medium (hESFM, Thermo Fisher, Waltham, MA, 
USA) supplemented with 1% bovine platelet-poor 
plasma-derived serum (PDS, Alfa Aesar, Ward Mill, MA, 
USA), 10 ng/mL bFGF and 10 μM retinoic acid (Sigma-
Aldrich)]. Upon eight days of differentiation, cells were 
removed by accutase (Corning) treatment and seeded as 
single cells on 24-well Transwells (polyester, 0.4 μm pore 
size; filter area 0.33  cm2, Corning) coated with a solu-
tion of collagen from human placenta (Sigma-Aldrich) 
and bovine plasma fibronectin (Sigma-Aldrich) (400 μg/
mL collagen IV and 100 μg/mL fibronectin) at a density 
of 1,000,000 cells/cm2. Twenty-four h after seeding, EC–
medium was added (EC medium supplemented with 1% 
platelet-poor derived serum). Purified endothelial mon-
olayers were formed on day 10 of the experiment, and 
permeability barrier function tests were performed 48 h 
after seeding on the Transwell system.
Measurement of barrier function
Barrier integrity of BMECs monolayer was obtained 
by measuring transendothelial electrical resistance 
(TEER) while using a Millicell ERS electrode (Millipore, 
Bedford, MA, USA). After conducting three measure-
ments for each insert (n = 3), the average resistance 
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was obtained. Paracellular permeability was assessed by 
adding 1 mg/mL of  [13C6] mannitol and  [13C12] sucrose 
to the donor site of the Transwell system. Then, 50 μL 
of aliquots were collected from the acceptor (basolat-
eral chamber) at 10, 20, 30, 60, and 120  min. At the 
end of the experiment, the donor and acceptor samples 
were diluted in water to be in the range of standard 
curve (10–1000 ng/mL) and the aforementioned prepa-
ration steps were performed to measure the concentra-
tions with UPLC–MS/MS system.
The clearance or permeability-surface area product 
(PS) for mannitol and sucrose were calculated using the 
following steps: First, the cleared volume up to each time 
point was calculated from the following equation. Then, 
linear regression applied to the plotted cleared volume 
versus time for samples and blank to obtain the PS of the 
Transwell system.
Here, Cacceptor referred to measured concentration in 
acceptor compartment at  a given sampling time point, 
and Vacceptor referred to the volume of acceptor compart-
ment. Also, C donor is the concentration in donor com-
partment. Afterwards, the permeability coefficient (P) 
was obtained by the following equations:
The permeability coefficient (P) was obtained by divid-
ing the PS to insert surface area (S)  (cm2) Eq.  (7), and 
then the permeability coefficient of the cell monolayer 
 (Pcells) was obtained by subtracting the permeability coef-
ficient of Transwell  (Ptotal) from the permeability coeffi-
cient of the coated filter  (Pblank) Eq. (8).
Measurement of permeability coefficient of Mannitol 
and Sucrose in presence of inflammatory cytokine
The effect of Interleukin 1 beta (IL-1β) on the perme-
ability of mannitol and sucrose in in vitro model of BBB 
(iPSC-derived BMECs) was also measured. To mimic 
inflammatory conditions, the Transwell model was 
exposed to media supplemented with 10 and 100 ng/mL 
IL-1β (Peprotech, Cranbury, NJ) for 24  h (n = 3). Then, 
the medium was removed, and fresh medium contain-
ing 1 mg/mL of sucrose and mannitol was added to the 
apical side of the Transwell. The permeability coefficients 
of markers were measured as previously described. Also, 
the TEER values of iPSC-derived BMECs were measured 
before and after exposure to IL-1β.
(6)
Cleared Volume = (C(acceptor) ∗ V (acceptor))/C(donor)
(7)P = PS/S
(8)
1
PCells
=
1
Ptotal
−
1
Pblank
Measurement of partition coefficients of Mannitol 
and Sucrose
By using an established method, the partition coef-
ficients of  [13C6]mannitol and  [13C12]sucrose between 
1-octanol and water were determined [15]. For this 
purpose, an equal volume of 1-octanol and water were 
mixed together at room temperature overnight with 
continuous stirring. Then 100 μg/mL of  [13C6]mannitol 
and  [13C12]Sucrose were added to 5 mL saturated water, 
and then the mixture was added to 5  mL of saturated 
1-octanol in a glass scintillation vial. Subsequently, 
the glass vial was placed in a rotary machine, and the 
content was mixed for 30  min. 500 μL samples were 
taken from both the water and 1-octanol phase for fur-
ther analysis with LC-MS/MS. The water samples are 
diluted 100-fold, and the 1-octanol samples remain 
undiluted for this purpose.
Statistical analysis
Statistical analysis of data was performed using Prism 8 
(GraphPad Software, La Jolla, CA). All experimental met-
rics were collected across at least three biological repli-
cates. The student’s paired t-test was used for comparison 
of uncorrected and corrected vascular space for the same 
mice. Unpaired two tailed t-test was used for compari-
son of two groups. Data with 3 groups were analyzed by 
1-way ANOVA, followed by Tukey’s multiple compari-
son test. In all cases, a p value < 0.05 was considered sig-
nificant. Data are presented as mean ± SD or individual 
values.
Results
Method development and validation
The mass spectra of  [13C12],  [13C6], and  [2H2]sucrose have 
been reported in our previous study [13]. The best m/z 
transition of stable isotopes of mannitol was selected 
based on signal to noise ratio and higher sensitivity, see 
Fig. S1 in Additional file 1.
Selectivity
Figure  1 depicts the chromatograms of single analyte 
neat samples of mannitol and sucrose prepared in water 
with no cross channel interference between transitions 
observed. We also showed the lowest calibration stand-
ard, blank matrix and internal standard in plasma and 
brain matrix (Fig. 2). We found no interference in matrix 
samples. However,  [13C6]sucrose (347 > 179) had a peak 
at retention time approx. 1.7 and 2.6 min in plasma and 
brain matrix, respectively. Also,  [2H2]sucrose transi-
tion (343 > 71) displayed the same peaks at the retention 
time of 1.7 and 2.7  min for plasma and brain matrix, 
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respectively. These peaks do not interfere with sucrose 
peak at the retention time of 2.2 min.
Accuracy and precision
The data for Inter- and Intra-run accuracy and precision 
in plasma and brain samples are included in Additional 
file 1: Table S1 and S2. Both plasma and brain values were 
within the limits of Food and Drug Administration (FDA) 
guidelines for the method validation. Moreover, the cali-
bration curves generated in the ranges of 10–1000 ng/mL 
and 5–400 ng/mL for plasma and brain, were found to be 
linear with  r2 > 0.99 across all Intra and Inter-assay runs.
Recovery and stability
Recoveries of  [13C6]mannitol,  [13C12]sucrose and  [13C6]
sucrose as the analytes of the method were performed for 
plasma and brain matrix at low, medium, and high con-
centrations. Based on Table S3, the recoveries of analytes 
were relatively high (≥ 95%) in all the tested matrices. 
Plus, the recovery of both sucrose analytes was similar to 
our previously developed method [13, 14]. In addition to 
high recovery, these data suggest minimal or no matrix 
effect on the analyte signal intensity.
The freeze–thaw stability of  [13C6]mannitol was deter-
mined for 50 and 500 ng/ml in water (Additional file 1: 
Fig. S2). The results confirmed that mannitol stays stable 
at three cycles of freeze–thaw that was similar to sucrose 
analytes in our previous study [13]. Results from the long 
Fig. 1 Chromatograms of single analyte neat samples of  [13C6]mannitol,  [
13C12]sucrose,  [
13C6] sucrose,  [
2H8]mannitol, and  [
2H2]sucrose, prepared in 
LC–MS/MS grade water, with all considered transitions
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term storage stability also showed mannitol was stable 
in plasma and brain matrix over the long term. Regard-
ing accuracy, the values of  [13C6]mannitol in plasma at 
nominal concentrations of 10, 100, and 1000 ng/mL were 
96.1%, 109%, and 97.6%, respectively. In case of brain 
matrix, the accuracy values for 5, 50 and 400  ng/mL 
nominal concentrations were 105%, 97.2%, and 97.5%, 
respectively.
In vivo application of the method
A comparative pharmacokinetic study was done in two 
groups of anesthetized C57BL/6J mice to show the appli-
cation of the method. The results of the pharmacokinetic 
study are shown in Figs. 3 and 4. The plasma profiles of 
both groups (vascular marker group and washout group) 
were similar for both mannitol and sucrose, and the areas 
under the curve from 0 to 30 min were not significantly 
different. Moreover, the plasma profile of mannitol was 
similar to sucrose, which showed a biexponential decline 
(Fig. 3).
Comparison of the corrected brain concentrations 
(washout vs. vascular marker correction) showed no 
significant difference for both mannitol and sucrose 
(unpaired, two-tailed t-test) (Fig.  4).  Cbr (%ID/mL) of 
mannitol was 0.071 ± 0.007 and 0.065 ± 0.009 for vas-
cular marker and washout respectively, whereas the 
 Cbr of sucrose was almost half of mannitol  Cbr values 
(0.035 ± 0.003 and 0.037 ± 0.005 for vascular marker and 
washout respectively). Similarly, comparison of the brain 
uptake clearance  (Kin) between these two groups of each 
marker showed no significant difference (unpaired, two-
tailed t-test) (Fig. 4). For example, The  Kin value of man-
nitol was 0.267 ± 0.021 μL/min g−1 and 0.245 ± 0.013 μL/
min  g−1 for the vascular marker and washout groups, 
respectively. In terms of comparison of two mark-
ers, the  Kin of mannitol (0.267 ± 0.021  µl  g−1  min−1) 
was more than two times higher than that of sucrose 
(0.126 ± 0.025 µl  g−1  min−1).
Fig. 2 Chromatograms of blank matrices, Lowest calibration standard and internal standard in plasma (a) and brain matrix (b)
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In vitro application of the method (in vitro‑in vivo 
correlation)
Transwell system is widely used in in  vitro models of 
BBB for drug development and screening [26]. We eval-
uated the permeability of our novel markers in iPSC 
derived brain endothelial cells cultured on the Transwell 
membranes. The barrier function of the monolayer was 
confirmed by measuring the TEER. The average TEER 
value was 1812 ± 54 Ω  cm2, which is similar to values 
reported in the literature [24, 27]. For a comparison 
between in  vitro and in  vivo models, the  Kin values or 
permeability surface area products (PS) were converted 
to permeability coefficients, taking 0.33  cm2/well as the 
surface area of the Transwell membranes, and 120 cm2/g 
of brain as the surface area of the BBB in vivo [23]. The 
in vitro permeability coefficient of mannitol and sucrose 
was 4.99 ± 0.152 × 10−7 and 3.12 ± 0.176 × 10−7, respec-
tively. Figure  5a depicts the permeability values of the 
two markers, with mannitol showing higher permeabil-
ity compared to sucrose (p < 0.0001 unpaired, two-tailed 
t-test). The PS value of mannitol and sucrose in vivo was 
0.267 ± 0.021 and 0.126 ± 0.025 µl  g−1  min−1 respectively, 
which corresponds to a permeability coefficient value 
of 3.71 ± 0.296 × 10−8 and 1.75 ± 0.355 × 10−8 cm/s for 
mannitol and sucrose, respectively. Figure 5c showed the 
in vitro and in vivo correlation of the markers. Interest-
ingly, the P values for mannitol and sucrose in vitro were 
only about 13-fold and 18-fold higher than the perme-
ability coefficient in vivo.
The effect of an inflammatory cytokine on the permea-
bility of BBB in the vitro model was examined. As shown 
in Fig.  6, the permeability coefficient of mannitol and 
sucrose significantly increased from 6.90 ± 0.689 × 10−7 
and 4.74 ± 0.314 × 10−7 to 1.67 ± 0.188 × 10−6 and 
1.23 ± 0.163 × 10−6, respectively, with 100  ng/mL IL-1β. 
Moreover, The TEER values of iPSC-derived BMECs 
decreased 38% after 1 day exposure to 100 ng/mL IL-1β. 
However, the decrease in the TEER values and increases 
in the permeability coefficients of sucrose and mannitol 
in the presence of 10 ng/mL IL-1β were not statistically 
significant (Fig. 6).
The correlations between log P (partition coefficient) 
and in  vitro and in  vivo permeability coefficients are 
shown in Fig.  7. We found that mannitol and sucrose 
have a log P of − 2.98 ± 0.033 and − 3.62 ± 0.056. The 
permeability coefficient of sucrose is lower compared to 
mannitol, reflecting the lower log P value.
Fig. 3 Pharmacokinetic profiles for  [13C6]mannitol and  [
13C12]sucrose in mouse plasma up to 30 min after IV bolus (mean ± SD, n = 6)
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Discussion
The results of our study showed we could accurately 
quantify the stable labeled isotopes of mannitol and 
sucrose simultaneously in brain and plasma by LCMS/
MS. Our method not only could replace radioactive 
tracers of mannitol and sucrose for permeability stud-
ies, but also it could detect two different molecular 
weight markers by one single run. The radioactive ver-
sion of mannitol has been used widely in the measure-
ment of the BBB [17–20, 27]. Moreover, mannitol is 
also used as a marker in the lactulose/mannitol (L/M) 
ratio test as a widespread dual-sugar test to assess the 
intestinal barrier function [16].  [13C]mannitol has been 
recently presented as a novel biomarker for quantifying 
the intestinal permeability [28, 29] but, the validation 
of  [13C]mannitol as a marker for the BBB has not been 
reported. Hence, the mass spectrometry condition of 
 [13C6]mannitol was optimized by continuous injection 
of mannitol solution with injection pump to get the 
optimum M–H−1. According to our findings, the most 
robust m/z value for  [13C6]mannitol was 187 → 92, 
based on signal to noise ratio.
The dual analytes with a vascular marker of sucrose 
were previously developed by our group. In our study, 
three analytes (one mannitol and two sucrose) plus two 
stable isotope internal standards were easily detected due 
to co-elution from a suitable stationary phase and vari-
ation of detector signal based on their molecular weight 
for each analyte. Figure 2 shows the simultaneous detect-
ability of mannitol and sucrose in the various matrices. 
Fig. 4 a, c Differences in brain concentration and brain uptake clearance  (Kin) of  [
13C6]mannitol with or without correction by vascular marker. b, d 
 Cbr and  Kin of  [
13C12]sucrose with or without correction by vascular marker. ***p < 0.001 (n = 6), analyzed by Student’s paired t‑test (two‑tailed). N.S. 
Student’s unpaired t‑test
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Co-administration of mannitol and sucrose could pro-
vide information on the uptake mechanism at the BBB 
of markers that have similar physicochemical properties 
over a range of molecular weights which covers the vast 
majority of marketed drugs [30]. The method has this 
feature to be run for single analyte by removing the tran-
sition of another anlayte from the method.
To indicate the application of our method in in  vitro 
studies, we used the Transwell system as the in vitro plat-
form most commonly used for BBB permeability stud-
ies. iPSC-derived BMECs were used, which provide high 
TEER values resulting in low paracellular permeability. 
The iPSC-derived BMECs is considered the ideal cell line 
for drug screening and permeability studies [31]. Vari-
ous BBB permeability markers are currently being used 
for Transwell models and advanced microfluidic models, 
including sodium fluorescein, radiolabeled sucrose, and 
different molecular weight dextrans [32]. Our method 
can quantify with high sensitivity and accuracy the integ-
rity of the BBB, when compared to radiolabeled versions 
of sucrose or mannitol, and the fluorescent dye sodium 
fluorescein, which all have drawbacks.
In terms of comparison between studies using radioac-
tive versions of mannitol and sucrose measured by liquid 
scintillation counting with their stable isotopes analyzed 
by LC–MS/MS, we have previously shown that  [14C]
sucrose had a 6 to sevenfold higher  Kin value in vivo than 
 [13C12]sucrose [15]. We also found by chromatographic 
fractionation of  [14C]sucrose after in  vivo administra-
tion that the majority of the brain content of measured 
14C radioactivity belonged to compounds other than the 
intact  [14C]sucrose [15]. Here, we found the  Kin of man-
nitol (0.267 ± 0.021) 3–7 fold lower than published values 
obtained with radioactive versions of mannitol  ([14C] and 
Fig. 5 a Permeability coefficient (P) of mannitol and sucrose in the Transwell model with TEER value of 1812 ± 54 Ω  cm2 (n = 3). b Permeability 
coefficient (P) of mannitol and sucrose in the vivo model (n = 6). ****p < 0.0001, analyzed by Student’s unpaired t‑test (two‑tailed). c In vitro and 
in vivo correlation of mannitol and sucrose based on the permeability coefficients
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Fig. 6 Permeability coefficient of a mannitol, b sucrose in iPSC‑BMECs following treatment with different concentrations of IL‑1β. c The effect of 
IL‑1β cytokine on TEER of iPSC‑BMECs. **p < 0.01 and ***p < 0.001, 1‑way ANOVA, followed by Tukey’s multiple comparisons test (n = 3)
Fig. 7 a Correlation of in vitro permeability coefficient (n = 3) and log P (n = 5). b Correlation of in vivo permeability coefficient (n = 6) and log P 
(n = 5)
Page 13 of 15Noorani et al. Fluids Barriers CNS           (2020) 17:61  
 [3H] mannitol) [18, 19, 33, 34]. Moreover, Preston and 
Haas reported 30–40% lower permeability area products 
of chromatographically purified  [3H]mannitol compared 
to stock solution of the same tracer lot [33, 35]. Compar-
ing the permeability values in different in  vitro studies 
is challenging due to major differences in experimen-
tal design in the published studies, including different 
sources of the endothelial cells and different culture con-
ditions, which also results in a range of different TEER 
values. Recent iPSC-derived BMECs in  vitro models 
reported similar permeability values (in the range of  10−6 
to  10−7 cm/s) for mannitol and sucrose as our values [24, 
36].
With respect to the small molecule fluorescent dye 
marker, sodium fluorescein, we have shown in previous 
work that, in order to avoid erroneous interpretation of 
brain uptake data, it is mandatory to perform a chroma-
tographic analysis of the unmetabolized (non-glucuro-
nidated) substance, and to measure the free fraction in 
plasma [37, 38]. Both is often neglected in publications 
using fluorescein in studies on BBB permeability. In addi-
tion, the potential role of efflux transporters for fluo-
rescein at the BBB has not been conclusively ruled out 
[39–41].
Recent advanced microfluidic BBB models (BBB-on-
a-chip) have reported general barrier restrictiveness by 
measuring paracellular flux with different molecular 
weights of dextran (ranging from 3 to 70  kDa). Report-
ing barrier function for large molecular weight markers 
may not accurately predict the integrity of BBB mod-
els for small, drug like molecules [42, 43]. Furthermore, 
permeability quantifications with such markers are not 
reliable in in  vivo experiments and result in inaccurate 
comparison between these advanced in vitro models and 
in vivo models. We obtained a permeability coefficient of 
4.99 ± 0.152 × 10−7 and 3.12 ± 0.176 × 10−7 for mannitol 
and sucrose, respectively. The permeability was found to 
be very low and showed the human in  vitro model has 
very tight barrier properties. Moreover, the precision 
and accuracy of the method supports its use for in vitro-
in vivo correlation studies with respect to permeability 
properties under healthy and disease conditions.
We also found that 100  ng/mL IL-1β resulted in a 
change of barrier function in the in  vitro model. This 
observation is similar to the previous in  vitro reports 
[44–46]. Additionally, there was a trend towards a 
decrease in the TEER value accompanied by an increase 
in the permeability coefficients for both markers at 
the 10  ng/mL concentration of IL-1β. However, these 
changes did not reach statistical significance (Fig.  6), 
most likely due to the small sample size used in our study 
(n = 3). The developed LC–MS/MS method was suc-
cessfully applied to measurements of plasma, and brain 
concentrations of mannitol and sucrose after injection 
of the markers to mice at a dose of 10 mg/kg. We previ-
ously showed that correcting vascular space using  [13C6]
sucrose was equally effective as buffer perfusion for 
determination of the BBB permeability of  [13C12]sucrose 
[13]. Interestingly, similar results were obtained when 
we used  [13C6]sucrose for correcting the vascular space 
of mannitol analyte in the brain (Fig.  4). The corrected 
 Kin and  Cbr of analytes showed no significant difference 
between the vascular marker and washout groups for 
both mannitol and sucrose. However, the uncorrected  Kin 
and concentration of brain indicated an overestimation, 
almost two times higher than the correct values, which 
demonstrates the impact of the intravascular content. In 
this context it is also apparent that correction of intravas-
cular volume needs to be performed in each individual 
animal, rather than by a value determined in a separate 
experimental series.
The correction method by vascular marker administra-
tion could be practically more advantageous compared 
to the washout method in several aspects: Technically, it 
is easier to perform, and brain tissue collection is attain-
able within seconds after the terminal blood sampling, 
as opposed to delays for several minutes by performing 
thoracotomy and perfusion (e.g., over 10 min in the pre-
sent study). Furthermore, rapid sampling gains impor-
tance when, apart from measuring the BBB permeability, 
parts of the brain samples were needed for measurement 
of other analytes such as neurotransmitters or metabo-
lites, that may undergo rapid degradation.
By comparing the PK profile of the two markers, we 
found that the plasma profiles of mannitol and sucrose 
were similar. However, the brain concentrations and  Kin 
of mannitol were almost two-fold higher than those for 
sucrose, which could be related to its lower molecular 
weight and higher paracellular diffusibility. An alternative 
explanation is the slightly higher lipid solubility of man-
nitol, with a log P of − 2.98 ± 0.033, which is half a log 
order higher than that of sucrose − 3.62 ± 0.055.
Conclusion
In conclusion, the newly developed method allows the 
measurement of triple analytes of mannitol and sucrose 
in the same sample in a single run. This technique sim-
plifies correction for intravascular plasma space in brain 
uptake experiments with sucrose or mannitol and makes 
a vascular washout step dispensable. In addition, non-
radiolabeled  [13C6]mannitol was introduced as BBB 
marker for the first time in this study. Last but not least, 
this method can now be considered as a very useful tool 
in quantifying BBB permeability in different in vitro and 
in  vivo disease models as well as for monitoring treat-
ment outcomes.
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